APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hereditary Angioedema Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Hereditary Angioedema Drug Industry Research Report 2026

20 December 2025124 pages

Choose your research edition.

Industry ResearchHereditary Angioedema Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hereditary Angioedema Drug Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Hereditary Angioedema Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hereditary Angioedema Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hereditary Angioedema Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Hereditary Angioedema Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Hereditary Angioedema Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Hereditary Angioedema Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Hereditary Angioedema Drug include Takeda, Pharming Group NV, Ionis Pharmaceuticals, Inc., IBio Inc., CSL Limited and BioCryst Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Hereditary Angioedema Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Hereditary Angioedema Drug Market by Company

Takeda

Pharming Group NV

Ionis Pharmaceuticals, Inc.

IBio Inc.

CSL Limited

BioCryst Pharmaceuticals, Inc.

Hereditary Angioedema Drug Segment by Type

C1 Esterase Inhibitor

Kallikrein Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Hereditary Angioedema Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hereditary Angioedema Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hereditary Angioedema Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hereditary Angioedema Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hereditary Angioedema Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Hereditary Angioedema Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Hereditary Angioedema Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Hereditary Angioedema Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hereditary Angioedema Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Hereditary Angioedema Drug Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Hereditary Angioedema Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Hereditary Angioedema Drug Revenue of Manufacturers (2021-2026) Table 9. Global Hereditary Angioedema Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Hereditary Angioedema Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Hereditary Angioedema Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Hereditary Angioedema Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Hereditary Angioedema Drug, Product Type & Application Table 14. Global Hereditary Angioedema Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Hereditary Angioedema Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Company Information Table 19. Takeda Business Overview Table 20. Takeda Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Takeda Hereditary Angioedema Drug Product Portfolio Table 22. Takeda Recent Developments Table 23. Pharming Group NV Company Information Table 24. Pharming Group NV Business Overview Table 25. Pharming Group NV Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Pharming Group NV Hereditary Angioedema Drug Product Portfolio Table 27. Pharming Group NV Recent Developments Table 28. Ionis Pharmaceuticals, Inc. Company Information Table 29. Ionis Pharmaceuticals, Inc. Business Overview Table 30. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 32. Ionis Pharmaceuticals, Inc. Recent Developments Table 33. IBio Inc. Company Information Table 34. IBio Inc. Business Overview Table 35. IBio Inc. Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. IBio Inc. Hereditary Angioedema Drug Product Portfolio Table 37. IBio Inc. Recent Developments Table 38. CSL Limited Company Information Table 39. CSL Limited Business Overview Table 40. CSL Limited Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. CSL Limited Hereditary Angioedema Drug Product Portfolio Table 42. CSL Limited Recent Developments Table 43. BioCryst Pharmaceuticals, Inc. Company Information Table 44. BioCryst Pharmaceuticals, Inc. Business Overview Table 45. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 47. BioCryst Pharmaceuticals, Inc. Recent Developments Table 48. Global Hereditary Angioedema Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 49. Global Hereditary Angioedema Drug Sales by Region (2021-2026) & (W Units) Table 50. Global Hereditary Angioedema Drug Sales Market Share by Region (2021-2026) Table 51. Global Hereditary Angioedema Drug Sales by Region (2027-2032) & (W Units) Table 52. Global Hereditary Angioedema Drug Sales Market Share by Region (2027-2032) Table 53. Global Hereditary Angioedema Drug Revenue by Region (2021-2026) & (US$ Million) Table 54. Global Hereditary Angioedema Drug Revenue Market Share by Region (2021-2026) Table 55. Global Hereditary Angioedema Drug Revenue by Region (2027-2032) & (US$ Million) Table 56. Global Hereditary Angioedema Drug Revenue Market Share by Region (2027-2032) Table 57. North America Hereditary Angioedema Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. North America Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 59. North America Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 60. North America Hereditary Angioedema Drug Revenue by Country (2021-2026) & (US$ Million) Table 61. North America Hereditary Angioedema Drug Revenue by Country (2027-2032) & (US$ Million) Table 62. Europe Hereditary Angioedema Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Europe Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 64. Europe Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 65. Europe Hereditary Angioedema Drug Revenue by Country (2021-2026) & (US$ Million) Table 66. Europe Hereditary Angioedema Drug Revenue by Country (2027-2032) & (US$ Million) Table 67. Asia Pacific Hereditary Angioedema Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Asia Pacific Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 69. Asia Pacific Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 70. Asia Pacific Hereditary Angioedema Drug Revenue by Country (2021-2026) & (US$ Million) Table 71. Asia Pacific Hereditary Angioedema Drug Revenue by Country (2027-2032) & (US$ Million) Table 72. South America Hereditary Angioedema Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. South America Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 74. South America Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 75. South America Hereditary Angioedema Drug Revenue by Country (2021-2026) & (US$ Million) Table 76. South America Hereditary Angioedema Drug Revenue by Country (2027-2032) & (US$ Million) Table 77. Middle East and Africa Hereditary Angioedema Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Middle East and Africa Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 79. Middle East and Africa Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 80. Middle East and Africa Hereditary Angioedema Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. Middle East and Africa Hereditary Angioedema Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. Global Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 83. Global Hereditary Angioedema Drug Sales by Type (2027-2032) & (W Units) Table 84. Global Hereditary Angioedema Drug Sales Market Share by Type (2021-2026) Table 85. Global Hereditary Angioedema Drug Sales Market Share by Type (2027-2032) Table 86. Global Hereditary Angioedema Drug Revenue by Type (2021-2026) & (US$ Million) Table 87. Global Hereditary Angioedema Drug Revenue by Type (2027-2032) & (US$ Million) Table 88. Global Hereditary Angioedema Drug Revenue Market Share by Type (2021-2026) Table 89. Global Hereditary Angioedema Drug Revenue Market Share by Type (2027-2032) Table 90. Global Hereditary Angioedema Drug Price by Type (2021-2026) & (US$/Unit) Table 91. Global Hereditary Angioedema Drug Price by Type (2027-2032) & (US$/Unit) Table 92. Global Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 93. Global Hereditary Angioedema Drug Sales by Application (2027-2032) & (W Units) Table 94. Global Hereditary Angioedema Drug Sales Market Share by Application (2021-2026) Table 95. Global Hereditary Angioedema Drug Sales Market Share by Application (2027-2032) Table 96. Global Hereditary Angioedema Drug Revenue by Application (2021-2026) & (US$ Million) Table 97. Global Hereditary Angioedema Drug Revenue by Application (2027-2032) & (US$ Million) Table 98. Global Hereditary Angioedema Drug Revenue Market Share by Application (2021-2026) Table 99. Global Hereditary Angioedema Drug Revenue Market Share by Application (2027-2032) Table 100. Global Hereditary Angioedema Drug Price by Application (2021-2026) & (US$/Unit) Table 101. Global Hereditary Angioedema Drug Price by Application (2027-2032) & (US$/Unit) Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Hereditary Angioedema Drug Distributors List Table 105. Hereditary Angioedema Drug Customers List Table 106. Hereditary Angioedema Drug Industry Trends Table 107. Hereditary Angioedema Drug Industry Drivers Table 108. Hereditary Angioedema Drug Industry Restraints Table 109. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Hereditary Angioedema Drug Product Image Figure 5. Global Hereditary Angioedema Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Hereditary Angioedema Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Hereditary Angioedema Drug Sales (2021-2032) & (W Units) Figure 8. Global Hereditary Angioedema Drug Average Price (US$/Unit) & (2021-2032) Figure 9. C1 Esterase Inhibitor Product Image Figure 10. Kallikrein Inhibitor Product Image Figure 11. Selective Bradykinin B2 Receptor Antagonist Product Image Figure 12. Hospital Pharmacies Product Image Figure 13. Online Pharmacies Product Image Figure 14. Retail Pharmacies Product Image Figure 15. Global Hereditary Angioedema Drug Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Hereditary Angioedema Drug, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Hereditary Angioedema Drug Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Hereditary Angioedema Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Hereditary Angioedema Drug Sales by Region in 2025 Figure 21. Global Hereditary Angioedema Drug Revenue by Region in 2025 Figure 22. North America Hereditary Angioedema Drug Market Size by Country in 2025 Figure 23. North America Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 24. North America Hereditary Angioedema Drug Revenue Market Share by Country (2021-2032) Figure 25. United States Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Hereditary Angioedema Drug Market Size by Country in 2025 Figure 28. Europe Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Hereditary Angioedema Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Netherlands Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Hereditary Angioedema Drug Market Size by Country in 2025 Figure 36. Asia Pacific Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Hereditary Angioedema Drug Revenue Market Share by Country (2021-2032) Figure 38. China Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Hereditary Angioedema Drug Market Size by Country in 2025 Figure 47. South America Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 48. South America Hereditary Angioedema Drug Revenue Market Share by Country (2021-2032) Figure 49. Mexico Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Colombia Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Hereditary Angioedema Drug Market Size by Country in 2025 Figure 54. Middle East and Africa Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Hereditary Angioedema Drug Revenue Market Share by Country (2021-2032) Figure 56. Turkey Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Hereditary Angioedema Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Hereditary Angioedema Drug Sales Market Share by Type (2021-2032) Figure 60. Global Hereditary Angioedema Drug Revenue Market Share by Type (2021-2032) Figure 61. Global Hereditary Angioedema Drug Price (US$/Unit) by Type (2021-2032) Figure 62. Global Hereditary Angioedema Drug Sales Market Share by Application (2021-2032) Figure 63. Global Hereditary Angioedema Drug Revenue Market Share by Application (2021-2032) Figure 64. Global Hereditary Angioedema Drug Price (US$/Unit) by Application (2021-2032) Figure 65. Hereditary Angioedema Drug Value Chain Figure 66. Hereditary Angioedema Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Hereditary Angioedema Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda
  • Pharming Group NV
  • Ionis Pharmaceuticals, Inc.
  • IBio Inc.
  • CSL Limited
  • BioCryst Pharmaceuticals, Inc.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Hereditary Angioedema Drug Market Size (2021-2032)
  4. 2.2.2 Global Hereditary Angioedema Drug Sales (2021-2032)
  5. 2.2.3 Global Hereditary Angioedema Drug Market Average Price (2021-2032)
  6. 2.3 Hereditary Angioedema Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 C1 Esterase Inhibitor
  9. 2.3.3 Kallikrein Inhibitor
  10. 2.3.4 Selective Bradykinin B2 Receptor Antagonist
  11. 2.4 Hereditary Angioedema Drug by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital Pharmacies
  14. 2.4.3 Online Pharmacies
  15. 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Hereditary Angioedema Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Hereditary Angioedema Drug Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Hereditary Angioedema Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Hereditary Angioedema Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Hereditary Angioedema Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Hereditary Angioedema Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Hereditary Angioedema Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Hereditary Angioedema Drug, Established Date
  9. 3.9 Global Hereditary Angioedema Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda
  2. 4.1.1 Takeda Company Information
  3. 4.1.2 Takeda Business Overview
  4. 4.1.3 Takeda Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Hereditary Angioedema Drug Product Portfolio
  6. 4.1.5 Takeda Recent Developments
  7. 4.2 Pharming Group NV
  8. 4.2.1 Pharming Group NV Company Information
  9. 4.2.2 Pharming Group NV Business Overview
  10. 4.2.3 Pharming Group NV Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pharming Group NV Hereditary Angioedema Drug Product Portfolio
  12. 4.2.5 Pharming Group NV Recent Developments
  13. 4.3 Ionis Pharmaceuticals, Inc.
  14. 4.3.1 Ionis Pharmaceuticals, Inc. Company Information
  15. 4.3.2 Ionis Pharmaceuticals, Inc. Business Overview
  16. 4.3.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  18. 4.3.5 Ionis Pharmaceuticals, Inc. Recent Developments
  19. 4.4 IBio Inc.
  20. 4.4.1 IBio Inc. Company Information
  21. 4.4.2 IBio Inc. Business Overview
  22. 4.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 IBio Inc. Hereditary Angioedema Drug Product Portfolio
  24. 4.4.5 IBio Inc. Recent Developments
  25. 4.5 CSL Limited
  26. 4.5.1 CSL Limited Company Information
  27. 4.5.2 CSL Limited Business Overview
  28. 4.5.3 CSL Limited Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 CSL Limited Hereditary Angioedema Drug Product Portfolio
  30. 4.5.5 CSL Limited Recent Developments
  31. 4.6 BioCryst Pharmaceuticals, Inc.
  32. 4.6.1 BioCryst Pharmaceuticals, Inc. Company Information
  33. 4.6.2 BioCryst Pharmaceuticals, Inc. Business Overview
  34. 4.6.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  36. 4.6.5 BioCryst Pharmaceuticals, Inc. Recent Developments
5 Global Hereditary Angioedema Drug Market Scenario by Region
  1. 5.1 Global Hereditary Angioedema Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Hereditary Angioedema Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Hereditary Angioedema Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Hereditary Angioedema Drug Sales by Region: 2027-2032
  5. 5.3 Global Hereditary Angioedema Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Hereditary Angioedema Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Hereditary Angioedema Drug Revenue by Region: 2027-2032
  8. 5.4 North America Hereditary Angioedema Drug Market Facts & Figures by Country
  9. 5.4.1 North America Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Hereditary Angioedema Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Hereditary Angioedema Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Hereditary Angioedema Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Hereditary Angioedema Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Hereditary Angioedema Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Hereditary Angioedema Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Hereditary Angioedema Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Hereditary Angioedema Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Hereditary Angioedema Drug Market Facts & Figures by Country
  35. 5.7.1 South America Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Hereditary Angioedema Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Hereditary Angioedema Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.7.7 Colombia
  42. 5.8 Middle East and Africa Hereditary Angioedema Drug Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Hereditary Angioedema Drug Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Hereditary Angioedema Drug Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Hereditary Angioedema Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Hereditary Angioedema Drug Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Hereditary Angioedema Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Hereditary Angioedema Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Hereditary Angioedema Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Hereditary Angioedema Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Hereditary Angioedema Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Hereditary Angioedema Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Hereditary Angioedema Drug Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Hereditary Angioedema Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Hereditary Angioedema Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Hereditary Angioedema Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Hereditary Angioedema Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Hereditary Angioedema Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Hereditary Angioedema Drug Value Chain Analysis
  2. 8.1.1 Hereditary Angioedema Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Hereditary Angioedema Drug Production Mode & Process
  5. 8.2 Hereditary Angioedema Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Hereditary Angioedema Drug Distributors
  8. 8.2.3 Hereditary Angioedema Drug Customers
9 Global Hereditary Angioedema Drug Analyzing Market Dynamics
  1. 9.1 Hereditary Angioedema Drug Industry Trends
  2. 9.2 Hereditary Angioedema Drug Industry Drivers
  3. 9.3 Hereditary Angioedema Drug Industry Opportunities and Challenges
  4. 9.4 Hereditary Angioedema Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst